Vertex Inks RNA Splicing Pact With Skyhawk

Paying $40m Upfront

In addition to its near-monopoly in cystic fibrosis, the US biotech behemoth is continuing its deal-making in other areas and has become the latest company to link up with Skyhawk.

Business Growth Concept_1089895325_1200.jpg
Vertex looking to grow business beyond cystic fibrosis • Source: Shutterstock

More from Deals

More from Business